Key Takeaways
- A randomized clinical trial involving 416 formula-fed infants found that adding milk fat globule membrane (MFGM) to infant formula did not significantly improve average cognitive scores at 12 months.
- Fewer infants receiving MFGM-enriched formula scored below the study’s threshold for cognitive delay at 12 months, but the difference was not statistically significant at 24 months.
- Earlier studies have produced mixed results, including short-term cognitive improvements that were not confirmed in later childhood.
- The findings do not justify switching infant formulas solely to improve a child’s cognitive development.
Introduction
A mother bottle-feeds her infant. A 2026 randomized trial found that MFGM-enriched infant formula did not significantly improve average cognitive scores at 12 months.
Can adding a component naturally present in breast milk make infant formula better for brain development?
That question has driven years of research into milk fat globule membrane (MFGM), a mixture of fats and proteins surrounding fat droplets in milk. Some manufacturers add bovine-derived MFGM to infant formula because its components participate in nervous system development.
But a randomized clinical trial published November 19, 2026, in JAMA Network Open found that MFGM-enriched formula did not significantly improve average cognitive scores at 12 months.
The study also produced an intriguing result: fewer infants receiving the enriched formula scored below a threshold used to identify possible cognitive delay.
Could an ingredient fail to improve average development yet still benefit children at the lower end of the developmental range? Or was the apparent difference a chance finding?
The trial provides useful evidence, but not a definitive answer.
What the Study Examined
Researchers led by Jacqueline F. Gould conducted a blinded randomized trial in Adelaide, Australia, involving 416 healthy, full-term infants who were exclusively formula-fed when they entered the study.
The infants were younger than two months when recruited between May 2020 and April 2022.
They were randomly assigned to receive one of two cow’s milk-based formulas:
- 207 infants received MFGM-enriched formula.
- 209 infants received standard formula without additional MFGM.
The formulas were matched for key nutrients apart from their MFGM content. Both contained some MFGM-related phospholipids, but the enriched formula contained a higher concentration.
Families used the assigned formula until their infants reached 12 months of age.
The researchers also enrolled 204 exclusively breastfed infants as a separate reference group. These children were not randomized, meaning comparisons with them cannot establish that breastfeeding itself caused differences in developmental scores.
The primary outcome was cognitive development at 12 months, assessed using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-IV). The assessment uses age-standardized scores with an expected mean of 100.
Children were assessed again at 24 months. Researchers also examined language, motor development, behavior, growth, feeding tolerance, and safety (Gould et al., 2026).
What Researchers Found
No Significant Improvement in Average Cognitive Scores
At 12 months, average cognitive scores were:
- 100.1 in the MFGM-enriched formula group.
- 99.4 in the standard formula group.
The adjusted difference was 0.68 points, with a 95% confidence interval from −1.94 to 3.31 points (P = .61).
The difference was not statistically significant.
Primary cognitive assessments were available for 382 of the 416 randomized infants, representing 91.8% of participants. Researchers used multiple imputation to account for missing outcome data in the main analysis.
The trial did not demonstrate that adding MFGM improved average cognitive development at 12 months. The confidence interval included the possibility of a small benefit or disadvantage, so the result does not prove that MFGM has no effect. However, it provides no convincing evidence of an average cognitive advantage from the enriched formula tested.
A Possible Benefit for Infants With Lower Scores
A secondary analysis produced a more encouraging result.
At 12 months, the estimated proportion of infants with cognitive scores below 85 was:
- 4.8% in the enriched-formula group.
- 11.5% in the standard-formula group.
That represents an absolute difference of 6.7 percentage points and an adjusted relative risk of 0.42, equivalent to a 58% lower relative risk.
These percentages came from analyses incorporating imputed data, not simply a count of children diagnosed with developmental disorders.
A Bayley-IV score below 85 identifies performance below a specified threshold. It is not, by itself, a clinical diagnosis of persistent developmental delay.
Although the result was statistically significant (P = .03), the researchers tested numerous secondary outcomes without adjusting for multiple comparisons. This increases the possibility of a chance finding.
At 24 months, the researchers did not find a statistically significant difference between the formula groups in the proportion of children scoring below the cognitive threshold. The adjusted relative risk was 0.85 (95% CI, 0.65–1.10; P = .20).
Average cognitive scores were also not significantly different at 24 months: 88.6 in the MFGM group versus 86.3 in the standard-formula group.
These findings do not confirm that the apparent benefit observed at 12 months persisted into the second year of life.
What About Language Development?
At 24 months, children in the enriched-formula group had slightly higher average language scores: 93.0 versus 90.0.
The initial adjusted difference was statistically significant, but it was no longer significant after an additional analysis accounted for differences in caregiver education.
Parent-reported language measures also showed no clear advantage.
Other developmental outcomes, growth measures, and safety results were largely similar between the two formula groups.
The trial found no statistically significant difference in serious adverse events, although this does not establish the safety of every MFGM formulation or rule out uncommon harms.
Why Earlier Studies Reached Different Conclusions
The new trial does not settle the MFGM debate because earlier research has produced conflicting findings.
In a Swedish randomized trial, 160 formula-fed infants were assigned to receive either an experimental formula containing bovine MFGM or a standard formula.
At 12 months, cognitive scores averaged 105.8 in the experimental group versus 101.8 in the control group, a statistically significant four-point difference (Timby et al., 2014).
However, the experimental formula also contained less energy and protein. That makes it difficult to attribute the cognitive difference exclusively to MFGM.
The same research team later evaluated children from the trial at approximately 6.5 years of age.
This time, investigators found no significant differences between the original formula groups in cognitive function, executive function, or behavior (Timby et al., 2021).
The contrast raises a central question: If an enriched formula improves an infant’s developmental test score, does that improvement persist into childhood?
A separate systematic review examined randomized trials of MFGM supplementation and found some promising results for cognition and other outcomes. However, the authors concluded that the evidence was too limited and inconsistent to establish firm clinical benefits (Ambrożej et al., 2021).
Differences between studies may reflect the type and dose of MFGM, other added ingredients, children’s ages, and the developmental assessments used.
The 2026 trial adds an important counterpoint because it tested MFGM enrichment in a relatively large randomized sample while keeping the formulas closely matched for other key nutrients.
Could MFGM Help Some Infants but Not Others?
The most interesting unanswered question is whether MFGM has a greater effect among infants who are more vulnerable to developmental difficulties.
A treatment can theoretically produce little change in the population average while affecting outcomes among a smaller subgroup.
But the new study did not establish that MFGM specifically benefits children at elevated developmental risk. The lower proportion of scores below 85 was a secondary outcome, and the difference was not confirmed at 24 months.
Another possibility is that MFGM’s effects depend on its composition.
Milk fat globule membrane contains phospholipids, gangliosides, and proteins with biological roles in cell membranes and nervous system development. Different commercial preparations contain different proportions of these components.
Results from one enriched formula therefore cannot automatically be applied to every formula advertised as containing MFGM.
Researchers still need to establish whether particular components, doses, or combinations produce lasting developmental benefits.
What About Breastfed Infants?
The breastfed reference group generally achieved higher developmental scores than the randomized formula-fed groups.
For example, the average cognitive score at 12 months was 104.9 among breastfed infants, compared with 100.1 and 99.4 in the two formula groups.
However, these comparisons were observational.
Families in the breastfed group differed from formula-feeding families in characteristics associated with child development, including caregiver education and home environment measures.
Consequently, the differences cannot be attributed solely to breast milk, MFGM, or any single nutritional component.
Nor does the study establish that adding MFGM makes formula developmentally equivalent to breastfeeding.
Limitations
The trial had several strengths, including randomized allocation, blinding, high follow-up, prespecified primary analyses, and developmental assessments extending to 24 months.
Nevertheless, important uncertainties remain.
First, the primary outcome was negative. The apparent reduction in cognitive delay was a secondary finding, and multiple comparisons increase the possibility of chance results.
Second, developmental test scores declined between the 12- and 24-month assessments across all three groups. Because the Bayley-IV uses age-standardized scores, this pattern should not be interpreted as evidence that the children’s cognitive abilities actually deteriorated. The researchers suggested that the assessment’s applicability and normative performance in Australian children may require further investigation.
Third, the study was conducted in one Australian metropolitan area. Participants were healthy, full-term infants from English-speaking households, limiting generalization to premature infants, children with complex medical conditions, and other populations.
Finally, follow-up ended at 24 months. The study cannot establish whether MFGM affects school-age learning, intellectual functioning, or longer-term development.
What the Results Mean for Parents
The findings do not provide convincing evidence that parents should choose or switch to an MFGM-enriched infant formula specifically to improve their child’s cognitive development.
Although fewer infants receiving the enriched formula scored below the study’s cognitive threshold at 12 months, this was a secondary finding that was not confirmed at 24 months.
For families using infant formula, choosing a product that is nutritionally appropriate for the child’s age and individual needs remains more important than an unconfirmed claim of improved brain development.
Parents whose babies are feeding well and growing appropriately should not interpret this study as a reason to change formulas. Families considering a switch because of feeding difficulties, allergies, growth concerns, or other medical needs should discuss the decision with their pediatric healthcare professional.
The study also does not establish that every MFGM-containing formula has identical effects because commercial products can differ in ingredient composition.
For now, the evidence supports cautious interpretation rather than a specific formula-purchasing recommendation.
Final Thoughts
This randomized trial adds important evidence to the debate over MFGM-enriched infant formula. Despite earlier reports of possible developmental benefits, researchers found no statistically significant improvement in average cognitive scores at 12 months.
The lower proportion of infants scoring below the cognitive threshold is worth investigating, but it remains uncertain whether that finding reflects a reproducible and lasting benefit.
Future research will need to determine whether specific MFGM preparations improve meaningful developmental outcomes beyond infancy. Until then, the evidence does not justify choosing an enriched formula solely for its proposed cognitive benefits.
Funding and Disclosures
The study was funded by Fonterra Co-Operative Group Limited, which also supplied the study formulas. Funding was paid to the South Australian Health and Medical Research Institute.
According to the published funding statement, Fonterra provided input into the study’s design and approved the manuscript. The authors reported that the company was not involved in conducting the trial, collecting or managing data, performing statistical analyses, interpreting the findings, preparing or reviewing the manuscript, or deciding whether to submit it for publication.
Two authors had Fonterra affiliations. Several researchers reported institutional funding or support from Fonterra. One author also disclosed consulting-related payments associated with Fonterra and separate consulting fees from Nestlé.
The paper reported additional Australian National Health and Medical Research Council support for two investigators.
These commercial relationships are relevant when interpreting research involving proprietary infant-formula ingredients.
References
Ambrożej, D., Dumycz, K., Dziechciarz, P., & Ruszczyński, M. (2021). Milk fat globule membrane supplementation in children: Systematic review with meta-analysis. Nutrients, 13(3), 714. https://doi.org/10.3390/nu13030714
Gould, J. F., Gibson, R. A., Yelland, L. N., Colombo, J., McPhee, A. J., Bednarz, J., Fong, B., Gallier, S., Roberts, R. M., Shaddy, D. J., & Makrides, M. (2026). Milk fat globule membrane–enriched formula and cognition among formula-fed infants: A randomized clinical trial. JAMA Network Open, 9(11), e2644537. https://doi.org/10.1001/jamanetworkopen.2026.44537
Timby, N., Domellöf, E., Hernell, O., Lönnerdal, B., & Domellöf, M. (2014). Neurodevelopment, nutrition, and growth until 12 mo of age in infants fed a low-energy, low-protein formula supplemented with bovine milk fat globule membranes: A randomized controlled trial. The American Journal of Clinical Nutrition, 99(4), 860–868. https://doi.org/10.3945/ajcn.113.064295
Timby, N., Adamsson, M., Domellöf, E., Grip, T., Hernell, O., Lönnerdal, B., & Domellöf, M. (2021). Neurodevelopment and growth until 6.5 years of infants who consumed a low-energy, low-protein formula supplemented with bovine milk fat globule membranes: A randomized controlled trial. The American Journal of Clinical Nutrition, 113(3), 586–592. https://doi.org/10.1093/ajcn/nqaa354




